[go: up one dir, main page]

ATE528408T1 - SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGET - Google Patents

SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGET

Info

Publication number
ATE528408T1
ATE528408T1 AT09709335T AT09709335T ATE528408T1 AT E528408 T1 ATE528408 T1 AT E528408T1 AT 09709335 T AT09709335 T AT 09709335T AT 09709335 T AT09709335 T AT 09709335T AT E528408 T1 ATE528408 T1 AT E528408T1
Authority
AT
Austria
Prior art keywords
multiple target
against multiple
interacting molecules
molecules against
pi3k
Prior art date
Application number
AT09709335T
Other languages
German (de)
Inventor
Andrew David Cansfield
Moore Giovanna Bergamini
Gitte Neubauer
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of ATE528408T1 publication Critical patent/ATE528408T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to methods wherein a PI3K interacting compound is identified by incubating a PI3K containing protein preparation with phenylthiazole ligand 1.
AT09709335T 2008-02-04 2009-02-03 SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGET ATE528408T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08002053 2008-02-04
PCT/EP2009/000692 WO2009098021A1 (en) 2008-02-04 2009-02-03 Selectivity profiling of pi3k interacting molecules against multiple targets

Publications (1)

Publication Number Publication Date
ATE528408T1 true ATE528408T1 (en) 2011-10-15

Family

ID=39561994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09709335T ATE528408T1 (en) 2008-02-04 2009-02-03 SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGET

Country Status (10)

Country Link
US (1) US20110111972A1 (en)
EP (2) EP2410062A1 (en)
JP (1) JP2011514965A (en)
CN (1) CN101965408B (en)
AT (1) ATE528408T1 (en)
AU (1) AU2009211845A1 (en)
CA (1) CA2713276A1 (en)
DK (1) DK2245181T3 (en)
ES (1) ES2375541T3 (en)
WO (1) WO2009098021A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414281T1 (en) 2006-08-03 2008-11-15 Cellzome Ag METHOD FOR IDENTIFYING MOLECULES THAT INTERACT WITH PI3K AND METHOD FOR PURIFYING PI3K
ES2529205T3 (en) 2009-03-13 2015-02-17 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
US20130210030A1 (en) 2010-07-19 2013-08-15 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP2694511A1 (en) 2011-04-04 2014-02-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
BR112014006743A8 (en) 2011-09-21 2018-01-09 Cellzome Ltd compound, use of a compound, and method for treating, controlling, retarding or preventing one or more conditions
US9242993B2 (en) 2011-10-07 2016-01-26 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
CN102977063A (en) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing 2-morpholine-8-phenyl-4-benzopyran-4-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525503A (en) * 1993-09-28 1996-06-11 Dana-Farber Cancer Institute, Inc. Signal transduction via CD28
US20030194749A1 (en) * 2002-02-15 2003-10-16 Wandless Thomas J. Wortmannin derivatives as probes of cellular proteins and processes
AR038703A1 (en) 2002-02-28 2005-01-26 Novartis Ag DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3
SE0402735D0 (en) * 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
EP1734367A1 (en) * 2005-06-14 2006-12-20 Cellzome Ag Process for the identification of novel enzyme interacting compounds
PL1891446T3 (en) 2005-06-14 2013-08-30 Cellzome Gmbh Process for the identification of novel enzyme interacting compounds
CN101300047A (en) * 2005-09-07 2008-11-05 雪兰诺实验室有限公司 PI3K inhibitors for the treatment of endometriosis
DK1866433T3 (en) * 2006-03-14 2009-08-17 Cellzome Ag Method for identifying LRRK-2 interacting molecules and for purifying LRRK2
ATE414281T1 (en) * 2006-08-03 2008-11-15 Cellzome Ag METHOD FOR IDENTIFYING MOLECULES THAT INTERACT WITH PI3K AND METHOD FOR PURIFYING PI3K

Also Published As

Publication number Publication date
JP2011514965A (en) 2011-05-12
CN101965408A (en) 2011-02-02
DK2245181T3 (en) 2012-02-06
CN101965408B (en) 2013-08-28
CA2713276A1 (en) 2009-08-13
EP2245181A1 (en) 2010-11-03
ES2375541T3 (en) 2012-03-01
WO2009098021A1 (en) 2009-08-13
HK1144705A1 (en) 2011-03-04
US20110111972A1 (en) 2011-05-12
EP2410062A1 (en) 2012-01-25
EP2245181B1 (en) 2011-10-12
AU2009211845A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ATE528408T1 (en) SELECTIVITY PROFILING OF PI3K INTERACTING MOLECULES AGAINST MULTIPLE TARGET
EA201170124A1 (en) POLYCHROMIUM SUBSTANCES AND THEIR APPLICATION
CY2017044I2 (en) ANTIBODIES TO CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
JOP20180102B1 (en) Pharmaceutical compound
EA200702670A1 (en) PREPARATION OF THYENOPYRIDINE INHIBITOR OF PLATELET AGGREGATION
UA110338C2 (en) CHEMICAL COMPOUNDS
EA200970402A1 (en) TRIAZOLOPIRIDAZIN PROTEINKINASE MODULATORS
BRPI1009637A2 (en) compound, composition and use of a compound
LT2889043T (en) SYNTHETIC INTERMEDIATE COMPOUNDS FOR THE MANUFACTURE OF OLIGOSACHARIDO-WHITE CONJECTION
IL223106B (en) "New antibodies to inhibit dimerization of c-met, and their uses."
BR112013026324A8 (en) aryl or heteroaryl substituted benzene compounds
EA201500173A1 (en) ФУНГИЦИДНЫЕ КОМПОЗИЦИИ
EA200901388A1 (en) INCREASE OF PLANT PRODUCTIVITY BY COMBINING CHEMICAL SUBSTANCES WITH TRANSGENIC MODIFICATIONS
CY1111793T1 (en) Fungal Ingredients
CO6640320A2 (en) Composition of phyto-disease control and method of phyto-disease control
BR112015018509A2 (en) imidazo pyridine compounds
EA201000250A1 (en) NEW SALT BASEDOXYPHENE
UY33196A (en) ANTICOAGULANT ANTIDOTES
EA200702363A1 (en) NEW HISTAMINE H-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
ATE511845T1 (en) USE OF ISOTHICYANATE DERVIATES AS MYELOMA-FIGHTING ACTIVES
UY32074A (en) PIRROL COMPOUNDS
EA201190179A1 (en) METHODS AND INTERMEDIATE CHEMICAL COMPOUNDS TO OBTAIN PHARMACEUTICAL MEANS
BRPI0821102A2 (en) Preparation of dihydropyrrol derivatives as intermediates
UY31688A1 (en) PESTICIDES
EA201690879A1 (en) NEW TRIAZOLOPIRIDINE CONNECTION

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2245181

Country of ref document: EP